Crossref
Mitochondrial-derived vesicles: Rethinking a quality control pathway as a therapeutic opportunity
Biomedicine Advances · 27.04.2026 · 3 (2) · 44-46
DOI: 10.34172/bma.68 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomedicine Advances, online erschienen am 27.04.2026. Verfasst von Fatima Elmusa und 1 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 10 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Elmusa, F., & Dastouri, M. (2026). Mitochondrial-derived vesicles: Rethinking a quality control pathway as a therapeutic opportunity. Biomedicine Advances, 3(2), 44-46. https://doi.org/10.34172/bma.68
Vancouver
Elmusa F, Dastouri M. Mitochondrial-derived vesicles: Rethinking a quality control pathway as a therapeutic opportunity. Biomedicine Advances. 2026;3(2):44-46. doi:10.34172/bma.68
BibTeX
@article{Elmusa2026,
author = {Elmusa, Fatima and Dastouri, Mohammadreza},
title = {Mitochondrial-derived vesicles: Rethinking a quality control pathway as a therapeutic opportunity},
journal = {Biomedicine Advances},
year = {2026},
volume = {3},
number = {2},
pages = {44--46},
doi = {10.34172/bma.68}
}
EUVIMED